Such a relationship would provide a firm with much more intensive oversight than is possible with a normal public corporation, as well as a longer-term perspective and assured funding???all of which are crucial for drug R&D. It would also allow the firm to operate with a significant degree of independence and to offer stock options and other incentives to attract and retain entrepreneurs.